Science ❯ Biotechnology ❯ Gene Therapy

Clinical Trials

Regulatory Processes AMT-130 Drug Development uniQure COVID-19 Vaccines Regulatory Affairs STXBP1 Encephalopathy Therapeutic Candidates Efficacy Studies Hemophilia Treatment Visual Function Restoration Ethical Concerns OTOF Gene Mutations Manufacturing Processes Funding Issues TET-101

Lilly Licenses MeiraGTx Eye Gene Therapy in Deal Worth Up to $475 Million

The agreement deepens Lilly’s push into ophthalmic gene medicines following its October move to buy Adverum Biotechnologies.

Lilly to Buy Adverum in Gene‑Therapy Deal Worth Up to $12.47 a Share

Capsida Halts STXBP1 Gene Therapy Trial After First Pediatric Participant Dies

Kriya Nets $320 Million Series D as Odyssey Raises $213 Million and Amgen Retools Research Leadership